Deccan Herald » Edit Page » Detailed Story
IN PERSPECTIVE
By Gopal Dabade
Deccan Herald
If patents are granted to a company, the price of the drug would be beyond the reach of the masses.
Just a few days back several groups of individuals, known popularly by their acronyms as INP+ and PWN, which stand for Indian Network of People [...]
No Comments »
Filed under: Article, TRIPS
Financial Express, June 20, 2007
The Intellectual Property Appellate Board (IPAB), which has been formed to give a verdict on various patent cases across the country, may reject Novartis objection on the presence of S Chandrasekharan, the former patent controller, on IPAB.
Novartis had objected to Chandrasekharans presence on the board saying he was responsible for Glivec [...]
No Comments »
Filed under: Article, News, Patent Litigation, TRIPS
The case filed by the big pharmaceutical company Novartis has attracted global attention. “Doctors Without Borders” winner of the Nobel Prize for best medical relief in 1999, has requested people all over the world to write to the company to drop the case. Over two lakh people have written to Novartis. Why is this [...]
No Comments »
Filed under: Article, Campaign
THE HINDU, May 01, 2007
Norwegian Minister of International Development Erik Solheim has urged Novartis to withdraw its case against India, challenging a clause of the Indian Patent (Amendment) Act, which does not grant patents to medicines that are new forms of an existing drug or “ever-greened” rather than innovations.
Last year, Doctors Without Borders (Mdecins [...]
No Comments »
Filed under: Article, News
In 1997, Novartis AG filed a patent application in the Chennai ( Madras) Patent Controller’s office for the beta-crystalline of Imatinib Mesylate, brand name Glivec (Gleevec) on the ground that they invented the beta crystalline salt form (imatinib mesylate) of the free base, imatinib. In 2003, it was granted Exclusive Marketing Rights (EMR) [...]
No Comments »
Filed under: Article, Campaign, News
Novartisboycott tagged on Del.icio.us